Corporate News Article Body

Incyte Corp. Secures FDA Approval for Jakafi XR and Expands Global Reach with Axatilimab

Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for its extended‑release formulation of ruxolitinib, marketed as Jakafi XR, for multiple indications in adults and, for certain conditions, in patients aged 12 and older. The approval encompasses intermediate‑to‑high‑risk myelofibrosis, polycythaemia vera patients who have failed hydroxyurea therapy, and both acute and chronic graft‑versus‑host disease (GvHD) after failure of one or two prior systemic treatments.

1. Clinical Rationale and Pharmacologic Profile

Ruxolitinib is a selective Janus kinase 1 and 2 (JAK1/2) inhibitor that modulates the downstream signaling of several cytokine receptors implicated in myeloproliferative neoplasms (MPNs) and immune‑mediated disorders such as GvHD. In its immediate‑release (IR) formulation, patients receive two oral tablets daily, resulting in peak‑to‑trough variations that can impact efficacy and safety. The newly approved extended‑release (XR) tablet delivers a sustained release of active drug over 24 hours, achieving a pharmacokinetic (PK) profile comparable to the twice‑daily IR product but with a simplified once‑daily dosing schedule.

Pre‑approval studies demonstrated bioequivalence between the XR and IR products in terms of area under the concentration–time curve (AUC) and maximum plasma concentration (Cmax). Importantly, the safety profile—primarily neutropenia, thrombocytopenia, and infection risk—remained consistent with the established data for the IR formulation, underscoring the clinical robustness of the XR design.

2. Regulatory Pathway and Trial Data

The FDA approval was based on a combination of pivotal phase‑III trials (e.g., COMFORT‑I for myelofibrosis, RESPONSE for polycythaemia vera) and a dedicated bioequivalence study (NCT03717621) that compared PK parameters and adverse event (AE) incidence between XR and IR. These studies collectively provided evidence that the XR formulation preserves therapeutic efficacy while improving patient adherence—a critical factor in chronic disease management.

For GvHD, data derived from the RUX‑GvHD trial (NCT02189673) showed that patients receiving Jakafi XR achieved similar response rates (overall response rate = ~55%) and complete response rates (≈ 30%) compared to historical controls treated with standard therapy, with no increase in serious AEs. The trial also confirmed that the XR formulation does not compromise the rapid onset of action needed for acute GvHD management.

The approval process adhered to the FDA’s Biologics License Application (BLA) pathway for small‑molecule drugs, with a focus on demonstrating both efficacy and safety in the expanded indication set. Post‑marketing commitments will include a phase‑IV study to monitor long‑term outcomes and safety signals across the newly authorized patient populations.

3. Business Impact and Strategic Positioning

Incyte’s CEO highlighted that the once‑daily XR formulation broadens therapeutic options for patients with MPNs and GvHD, potentially improving medication adherence and reducing healthcare costs associated with treatment failure and hospitalizations. The company reiterated its commitment to patient support via an access program that facilitates insurance navigation, patient education, and financial assistance—a critical component for maximizing real‑world uptake of the new therapy.

The FDA milestone enhances Incyte’s portfolio of targeted kinase inhibitors and solidifies its leadership in the hematology space. By providing a convenient dosing schedule without compromising efficacy, Incyte positions itself favorably against competitors offering multi‑daily regimens or alternative JAK inhibitors with less favorable safety profiles.

4. International Expansion: Axatilimab Approval in Australia

Complementing the U.S. approval, the Therapeutic Goods Administration (TGA) in Australia has granted clearance for axatilimab—an anti‑colony stimulating factor‑1 receptor (CSF‑1R) monoclonal antibody—for chronic GvHD in patients who have received at least two prior therapies. This decision followed a global phase‑II trial (NCT03339861) that reported a response rate of 38% and a manageable AE profile, primarily mild to moderate infusion reactions and transient cytopenias.

Axatilimab represents a first‑in‑class approach targeting CSF‑1R, a receptor implicated in the recruitment and activation of macrophages that drive chronic GvHD pathology. By inhibiting CSF‑1R, axatilimab disrupts the cytokine milieu that sustains alloreactive immune responses, offering a mechanistically distinct therapeutic option relative to JAK inhibitors.

Incyte’s exclusive partnership with Specialized Therapeutics grants commercial rights to axatilimab in Australia, New Zealand, and Singapore, aligning with Incyte’s strategy to expand its reach in the Asia‑Pacific region and diversify its product pipeline beyond JAK inhibition.

5. Conclusion

The dual regulatory approvals—FDA clearance for Jakafi XR and TGA authorization for axatilimab—mark significant milestones for Incyte. They underscore the company’s commitment to advancing precision medicine in hematology, providing clinicians with evidence‑based, patient‑friendly therapies for MPNs and GvHD. While the clinical data supporting these products are robust, continued surveillance and post‑marketing studies will be essential to confirm long‑term efficacy and safety in diverse patient populations.

Incyte’s integrated strategy—combining scientifically grounded drug development, rigorous regulatory compliance, and comprehensive patient support—positions the company to capitalize on these approvals while addressing unmet needs in complex blood disorders and post‑transplant complications.